新华制药(000756) - 2016 Q4 - 年度财报

Financial Performance - In 2016, the company's operating revenue reached RMB 4,014,963,065.74, representing an increase of 11.62% compared to RMB 3,597,033,209.79 in 2015[11]. - The net profit attributable to shareholders of the listed company was RMB 122,271,549.68, a significant increase of 47.20% from RMB 83,062,257.17 in the previous year[11]. - The total profit of the company for 2016 was RMB 159,968,492.21, which is a 35.88% increase from RMB 117,729,615.03 in 2015[11]. - The company reported a net cash flow from operating activities of RMB 439,348,332.79, which is an increase of 26.02% compared to RMB 348,636,176.12 in 2015[11]. - The basic earnings per share for 2016 were RMB 0.27, up 50.00% from RMB 0.18 in 2015[11]. Assets and Liabilities - The total assets of the company at the end of 2016 were RMB 4,722,785,963.84, reflecting a growth of 5.13% from RMB 4,492,122,436.63 at the end of 2015[11]. - The total liabilities increased by 5.40% to RMB 2,643,478,538.19 at the end of 2016, compared to RMB 2,508,040,118.23 at the end of 2015[11]. - The group's asset-liability ratio stands at 55.97%, calculated as total liabilities divided by total assets multiplied by 100%[143]. Shareholder Information - The largest shareholder, Shandong Xinhua Pharmaceutical Group Co., Ltd., holds 34.46% of the shares, totaling 157,587,763 shares[19]. - The second largest shareholder, Hong Kong Central Clearing Limited, holds 32.56% of the shares, totaling 148,883,698 shares[19]. - The total number of shareholders increased from 29,550 to 34,395 during the reporting period[18]. - The company has a total of 457,312,830 shares, with 99.998% being tradable without restrictions[19]. Corporate Governance - The company has strengthened its corporate governance, ensuring compliance with relevant laws and regulations, and maintaining effective decision-making and supervisory processes[60]. - The company has not reported any shareholdings by its directors and supervisors as of December 31, 2016, indicating a potential focus on corporate governance and transparency[39]. - The independent supervisory board includes members with legal and financial expertise, enhancing the company's governance framework[34]. - The company has established a system for accountability regarding significant errors in annual report disclosures to enhance transparency and accuracy[193]. Employee Information - The company had a total of 6,346 employees as of December 31, 2016, with a total salary expenditure of RMB 371.482 million[48]. - The total remuneration for directors, supervisors, and senior management in 2016 amounted to RMB 8.184 million[45]. - The company completed 64 training programs in 2016, training 4,032 employees, and sent 157 employees for external training[49]. Research and Development - The company is actively involved in the pharmaceutical industry, with a commitment to research and development, as evidenced by the qualifications of its management team[32]. - The company successfully passed 141 audits, including a zero-defect inspection by the US FDA for 14 products[115]. - The company established several research collaborations, including a joint research center with the Chinese Academy of Medical Sciences[115]. Market Performance - Revenue from chemical raw materials grew by 19.79%, while revenue from formulation industry increased by 7.85%[114]. - The sales revenue of chemical raw materials reached RMB 1,770,296,000, up 19.79% from the previous year[127]. - The sales revenue of formulation products was RMB 1,747,611,000, an increase of 5.36% year-on-year[127]. Compliance and Auditing - The company received a standard unqualified audit report from ShineWing Certified Public Accountants for the 2016 financial report, confirming that the financial statements accurately reflect the company's financial position as of December 31, 2016[57]. - The company's financial statements for 2016 were deemed accurate and compliant with accounting standards by the audit committee[56]. - The internal control audit report issued by the accounting firm indicates that the company maintained effective financial reporting internal controls as of December 31, 2016[72]. Future Plans - The company plans to consider distributing a special dividend after the completion of a non-public issuance of A shares[6]. - The company plans to complete a non-public offering of A-shares, expected to raise over RMB 600 million, enhancing employee cohesion and company vitality[118]. - The company is actively pursuing international project cooperation and product international registration to enhance growth[120].